Skip to main content

Lisocabtagene Maraleucel Dosage

Medically reviewed by Last updated on Mar 8, 2024.

Usual Adult Dose for Lymphoma



A single dose of this drug contains 50 to 110 x 106 CAR-positive viable T cells (consisting of 1:1 CAR-positive viable T cells of the CD8 and CD4 components), with each component supplied separately in 1 to 4 single-dose vials. Each mL contains 1.5 x 10(6) to 70 x 10(6) CAR-positive viable T cells (3).See the respective Certificate of Release for Infusion (RFI Certificate) for each component, for the actual cell counts and volumes to be infused.

1) Use IV normal saline to flush all the infusion tubing prior to and after each CD8 or CD4 component administration.
2) Administer the entire volume of the CD8 component IV at an infusion rate of approximately 0.5 mL/min, using the closest port or Y-arm. NOTE: The time for infusion will vary but will usually be less than 15 minutes for each component.
3) If more than one syringe is required for a full cell dose of the CD8 component, administer the volume in each syringe consecutively without any time between administering the contents of the syringes (unless there is a clinical reason [e.g., infusion reaction] to hold the dose).
4) After the CD8 component has been administered, flush the tubing with normal saline, using enough volume to clear the tubing and the length of the IV catheter. 5) Administer the CD4 component second, immediately after administration of the CD8 component is complete, using steps 1 through 4, as described for the CD8 component. Following administration of the CD4 component, flush the tubing with normal saline, using enough volume to clear the tubing and the length of the IV catheter.


Use: For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B (this drug is not indicated for the treatment of patients with primary central nervous system [CNS] lymphoma)

Renal Dose Adjustments

Data not available
See the prescribing information for fludarabine and cyclophosphamide for information on dose adjustment in renal impairment.

Liver Dose Adjustments

Data not available

Dose Adjustments

GRADE 1 (fever):

GRADE 2 (symptoms require and respond to moderate intervention; oxygen requirement less than 40% FiO2, or hypotension responsive to fluids or low dose of one vasopressor, or Grade 2 organ toxicity):
GRADE 3 (symptoms require and respond to aggressive intervention; oxygen requirement greater than or equal to 40% FiO2, or hypotension requiring high-dose or multiple vasopressors, or Grade 3 organ toxicity, or Grade 4 transaminitis):
GRADE 4 (life-threatening symptoms; requirements for ventilator support or continuous veno-venous hemodialysis [CVVHD] or Grade 4 organ toxicity [excluding transaminitis]):
Do not exceed 3 doses tocilizumab in 24 hours, or 4 doses total.



The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for Breyanzi. It includes elements to assure safe use, and implementation system. For additional information:




Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Storage requirements:

IV compatibility:


Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.